Clinical significance of Koebner phenomenon in vitiligo

British Journal of Dermatology

Volumn 167, Issue 5, 2012, Pages 1017-1024

  Van Geel, N ^a   Speeckaert, R ^a   De Wolf, J ^a   Bracke, S ^a   Chevolet, I ^a   Brochez, L ^a   Lambert, J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; AUTOIMMUNE DISEASE; BODY REGIONS; BODY SURFACE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PRACTICE; DEPIGMENTATION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HUMAN; INCIDENCE; ISOMORPHIC PHENOMENON; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN INJURY; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VITILIGO;

ADULT; AGE OF ONSET; COHORT STUDIES; FEMALE; HUMANS; MALE; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SKIN; VITILIGO; WOUND HEALING;

EID: 84868201977     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11158.x     Document Type: Article

References (15)

1. Köbner H,. Zur aetiologie der psoriasis. Vjschr Dermatol 1876; 8: 559-61.
2. Miller RA,. The Koebner phenomenon. Int J Dermatol 1982; 21: 192-7.
3. Njoo MD, Das PK, Bos JD, et al. Association of the Koebner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 1999; 135: 407-13.
4. Mazereeuw-Hautier J, Bezio S, Mahe E, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol 2010; 62: 945-9.
5. Barona MI, Arrunategui A, Falabella R, et al. An epidemiologic case-control study in a population with vitiligo. J Am Acad Dermatol 1995; 33: 621-5.
6. Hann SK, Park YK, Chun WH,. Clinical features of vitiligo. Clin Dermatol 1997; 15: 891-7.
7. van Geel N, Vandenhaute S, Speeckaert R, et al. Prognostic value and clinical significance of halo naevi regarding vitiligo. Br J Dermatol 2011; 164: 743-9.
8. van Geel N, Speeckaert R, Taieb A, et al. Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 2011; 24: 564-73.
9. van Geel N, Speeckaert R, Mollet I, et al. In vivo vitiligo induction and therapy model: double-blind, randomized clinical trial. Pigment Cell Melanoma Res 2012; 25: 57-65.
10. Birlea SA, Jin Y, Bennett DC, et al. Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol 2011; 131: 371-81.
11. Glimcher LH,. XBP1: the last two decades. Ann Rheum Dis 2010; 69 (Suppl. 1): i67-71.
12. He R, Geha RS,. Thymic stromal lymphopoietin. Ann N Y Acad Sci 2010; 1183: 13-24.
13. Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10: 744-55.
14. Eschler DC, Hasham A, Tomer Y,. Cutting edge: the etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol 2011; 41: 190-7.
15. Westerhof W, Manini P, Napolitano A, et al. The haptenation theory of vitiligo and melanoma rejection: a close-up. Exp Dermatol 2011; 20: 92-6.